全文获取类型
收费全文 | 757篇 |
免费 | 46篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 55篇 |
妇产科学 | 9篇 |
基础医学 | 67篇 |
口腔科学 | 16篇 |
临床医学 | 101篇 |
内科学 | 190篇 |
皮肤病学 | 7篇 |
神经病学 | 19篇 |
特种医学 | 163篇 |
外科学 | 72篇 |
综合类 | 12篇 |
预防医学 | 27篇 |
眼科学 | 13篇 |
药学 | 44篇 |
肿瘤学 | 41篇 |
出版年
2024年 | 2篇 |
2023年 | 3篇 |
2021年 | 8篇 |
2020年 | 5篇 |
2019年 | 6篇 |
2018年 | 12篇 |
2017年 | 9篇 |
2016年 | 7篇 |
2015年 | 8篇 |
2014年 | 16篇 |
2013年 | 21篇 |
2012年 | 16篇 |
2011年 | 16篇 |
2010年 | 42篇 |
2009年 | 41篇 |
2008年 | 27篇 |
2007年 | 44篇 |
2006年 | 31篇 |
2005年 | 28篇 |
2004年 | 9篇 |
2003年 | 8篇 |
2002年 | 11篇 |
2001年 | 13篇 |
2000年 | 7篇 |
1999年 | 9篇 |
1998年 | 48篇 |
1997年 | 48篇 |
1996年 | 45篇 |
1995年 | 40篇 |
1994年 | 41篇 |
1993年 | 26篇 |
1992年 | 4篇 |
1991年 | 13篇 |
1990年 | 13篇 |
1989年 | 26篇 |
1988年 | 23篇 |
1987年 | 12篇 |
1986年 | 16篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1980年 | 10篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1977年 | 10篇 |
1976年 | 6篇 |
1975年 | 3篇 |
1965年 | 1篇 |
排序方式: 共有839条查询结果,搜索用时 15 毫秒
831.
832.
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments 总被引:6,自引:0,他引:6
下载免费PDF全文
![点击此处可从《Genome research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Diskin SJ Eck T Greshock J Mosse YP Naylor T Stoeckert CJ Weber BL Maris JM Grant GR 《Genome research》2006,16(9):1149-1158
Regions of gain and loss of genomic DNA occur in many cancers and can drive the genesis and progression of disease. These copy number aberrations (CNAs) can be detected at high resolution by using microarray-based techniques. However, robust statistical approaches are needed to identify nonrandom gains and losses across multiple experiments/samples. We have developed a method called Significance Testing for Aberrant Copy number (STAC) to address this need. STAC utilizes two complementary statistics in combination with a novel search strategy. The significance of both statistics is assessed, and P-values are assigned to each location on the genome by using a multiple testing corrected permutation approach. We validate our method by using two published cancer data sets. STAC identifies genomic alterations known to be of clinical and biological significance and provides statistical support for 85% of previously reported regions. Moreover, STAC identifies numerous additional regions of significant gain/loss in these data that warrant further investigation. The P-values provided by STAC can be used to prioritize regions for follow-up study in an unbiased fashion. We conclude that STAC is a powerful tool for identifying nonrandom genomic amplifications and deletions across multiple experiments. A Java version of STAC is freely available for download at http://cbil.upenn.edu/STAC. 相似文献
833.
Although the dominant approach to drug development is the design of compounds selective for a given target, compounds targeting more than one biological process may have superior efficacy, or alternatively a better safety profile than standard selective compounds. Here, this possibility has been explored with respect to the endocannabinoid system and pain. Compounds inhibiting the enzyme fatty acid amide hydrolase (FAAH), by increasing local endocannabinoid tone, produce potentially useful effects in models of inflammatory and possibly neuropathic pain. Local increases in levels of the endocannabinoid anandamide potentiate the actions of cyclooxygenase inhibitors, raising the possibility that compounds inhibiting both FAAH and cyclooxygenase can be as effective as non-steroidal anti-inflammatory drugs but with a reduced cyclooxygenase inhibitory ‘load’. An ibuprofen analogue active in models of visceral pain and with FAAH and cyclooxygenase inhibitory properties has been identified. Another approach, built in to the experimental analgesic compound N-arachidonoylserotonin, is the combination of FAAH inhibitory and transient receptor potential vanilloid type 1 antagonist properties. Although finding the right balance of actions upon the two targets is a key to success, it is hoped that dual-action compounds of the types illustrated in this review will prove to be useful analgesic drugs. 相似文献
834.
Solberg BC Dirksen CD Nieman FH van Merode G Poeze M Ramsay G 《Critical care (London, England)》2008,12(3):R68
Introduction
The high cost of critical care resources has resulted in strategies to reduce the costs of ruling out low-risk patients by developing intermediate care units (IMCs). The aim of this study was to compare changes in total hospital costs for intensive care patients before and after the introduction of an IMC at the University Hospital Maastricht. 相似文献835.
CJ. Zhao C. Noack M. Brackmann T. Gloveli A. Maelicke U. Heinemann R. Anand K.H. Braunewell 《Molecular and cellular neurosciences》2009,40(2):280-292
The neuronal Ca2+-sensor protein VILIP-1, known to affect clathrin-dependent receptor trafficking, has been shown to interact with the cytoplasmic loop of the α4-subunit of the α4β2 nicotinic acetylcholine receptor (nAChR), which is the most abundant nAChR subtype with high-affinity for nicotine in the brain. The α4β2 nAChR is crucial for nicotine addiction and the beneficial effects of nicotine on cognition. Its dysfunction has been implicated in frontal lobe epilepsy, Alzheimer's disease and schizophrenia. Here we report that overexpression of VILIP-1 enhances ACh responsiveness, whereas siRNA against VILIP-1 reduces α4β2 nAChR currents of hippocampal neurons. The underlying molecular mechanism likely involves enhanced constitutive exocytosis of α4β2 nAChRs mediated by VILIP-1. The two interaction partners co-localize in a Ca2+-dependent manner with syntaxin-6, a Golgi-SNARE protein involved in trans-Golgi membrane trafficking. Thus, we speculate that regulation of VILIP-1-expression might modulate surface expression of ligand-gated ion channels, such as the α4β2 nAChRs, possibly comprising a novel form of physiological up-regulation of ligand-gated ion channels. 相似文献
836.
BACKGROUND: While interruption of angiotensin synthesis and angiotensin blockade are well know to reduce proteinuria and preserve renal function in patients with diabetic glomerulosclerosis, many patients still have significant proteinuria after having reached maximal doses of those medications. We chose to examine the effect of the addition of pentoxifylline to the therapeutic regimen of patients with significant proteinuria and chronic renal insufficiency who had reached maximal does of an angiotensin-converting enzyme inhibitor (ACEI) and an angiotensin receptor blocker (ARB), on the reduction of proteinuria and the preservation of renal function. METHODS: Seven male patients with diabetic glomerulosclerosis with proteinuria of at least 1.5 g/24 hours and a creatinine clearance of at least 15 ml/min despite maximal doses of an ACEI and an ARB for over 12 months were treated with pentoxifylline adjusted for creatinine clearance. They were then compared with 7 similar patients matched for age, duration of medications, proteinuria, creatinine clearance and mean arterial pressure. The groups were compared for any significant differences on at baseline and at 12 months. RESULTS: Although proteinuria decreased in the pentoxifylline group (5.657 +/- 3.5227 to 3.799 +/- 3.647 g/24 hours) there was no significant difference from the control group (4.743 +/- 2.320 to 4.986 +/- 2.941 g/24 hours). Similarly both groups lost creatinine clearance (41.0 +/- 27.44 to 29.33 +/- 22.21 ml/min with pentoxifylline and 45.57 +/- 21.854 to 27.33 +/- 27.105 ml/min in controls), but there was no significant difference in either clearance or mean arterial pressure. CONCLUSION: Although there was a trend toward the reduction of proteinuria, we found no statistical benefit in proteinuria reduction or preservation of renal function by the addition of pentoxifylline to maximal doses of ACEIs and ARBs. 相似文献
837.
Askari N Diskin R Avitzour M Yaakov G Livnah O Engelberg D 《Molecular and cellular endocrinology》2006,252(1-2):231-240
Constitutively active mutants that acquired intrinsic activity and escaped regulation, serve as powerful tools for revealing the biochemical, biological and pathological functions of proteins. Such mutants are not available for mitogen-activated protein kinases (MAPKs). It is not known how to mimic the unusual mode of MAPK activation and to enforce, by mutations, their active conformation. In this review we describe the strategies employed in attempts to overcome this obstacle. We focus on a recent breakthrough with the p38 family that suggests that active variants of all MAPKs will soon be available. 相似文献
838.
839.
Charles J. Diskin Ricardo Maldonado Jose Leon Linda M. Dansby Thomas B. Carter Lautrec Radcliff Charles D. Diskin 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2023,27(1):170-176